InMed Pharmaceuticals Inc. (INM) is a biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative medicines with a focus on cannabinoid-based therapies. The company is headquartered in Vancouver, Canada, and since it was established, it has been making strides in advancing the science and understanding of cannabinoids for various medical applications.
InMed's research and development strategy is grounded in their proprietary biosynthesis process, which they believe offers significant advantages over other methods of cannabinoid production. Their proprietary system includes the method of manufacturing cannabinoids in E. coli bacteria, allowing for the cost-effective, scalable, high-quality, and reliable production of all 100+ naturally-occurring cannabinoids.
The company's product pipeline include INM-755, a cream meant for treating epidermolysis bullosa (EB), a rare genetic condition that causes the skin to blister easily. InMed is also developing INM-088, which is aimed at reducing intraocular pressure in patients with glaucoma, one of the leading causes of blindness. These are indicative of InMed’s commitment to developing novel therapies for diseases with high unmet medical needs.
Their proprietary bioinformatics database assessment tool assists in the identification of cannabinoid compounds that may have potential positive effects on specific diseases. This tool uses algorithms which integrate data from numerous bioinformatics databases related to disease genetics, protein structures, and gene-disease relations.
InMed Pharmaceuticals also boasts a dedicated and highly experienced team of seasoned pharmaceutical scientists with a diversity of relevant skills that drives the company’s development efforts. The team's expertise spans a wide range of disciplines including drug discovery, preclinical and clinical development, manufacturing, intellectual property protection, and regulatory affairs.
However, InMed Pharmaceuticals, like other biotech companies, carries risks associated with the success of its research outcomes, regulatory approvals, commercial viability of its products and competition from other companies. The stock value is determinant on the company’s ability to deliver on its objectives, deliver results from their trial data, gain necessary regulatory approvals, secure partners and generate revenue.
InMed Pharmaceuticals is traded under the ticker symbol “INM” on the Nasdaq. Over the years, the company continues to show promise with their commitment to leading the way in cannabinoid science and creating valuable new medicines for patients suffering from chronic illnesses and diseases.
In conclusion, InMed Pharmaceuticals Inc. is a promising player in the biopharmaceutical sector, breaking new ground with its unique focus on cannabinoid-based medicine. Its commitment to addressing unmet medical needs, coupled with its innovative approach, positions it as a company with significant potential in the ever-evolving world of medical science.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Mentari Therapeutics has completed its merger with InMed Pharmaceuticals and secured $490 million in financing, with its shares beginning to trade on Nasdaq under the symbol "MTRI". The company is advancing a pipeline of biologics for migraine prevention, including MT-001 and MT-002, with initial clinical data expected in 2027. This funding provides runway into 2029, supporting the development of next-generation migraine therapies.
InMed Pharmaceuticals Inc. has completed its merger with privately held Mentari Therapeutics, Inc., and will now operate under the name Mentari Therapeutics, Inc. The combined company's shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol "MTRI" on November 9, 2026. This merger followed InMed's redomestication to Nevada and pre-merger Mentari's private financings totaling approximately $490 million.